BioNTech SE (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages

BioNTech SE (NASDAQ:BNTX) has been given an average recommendation of “Moderate Buy” by the seventeen brokerages that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $142.72.

A number of research analysts have recently issued reports on the stock. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Berenberg Bank assumed coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Finally, TD Cowen reduced their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th.

BioNTech Trading Down 2.4 %

NASDAQ BNTX opened at $119.83 on Monday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a market capitalization of $28.73 billion, a price-to-earnings ratio of -57.06 and a beta of 0.17. The company’s fifty day moving average price is $117.22 and its two-hundred day moving average price is $109.62.

Hedge Funds Weigh In On BioNTech

Several large investors have recently bought and sold shares of BNTX. FMR LLC increased its stake in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after buying an additional 5,598,190 shares during the period. Fred Alger Management LLC acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $59,485,000. Capital International Investors grew its stake in shares of BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company’s stock worth $161,304,000 after purchasing an additional 394,434 shares during the last quarter. Braidwell LP acquired a new position in shares of BioNTech in the 3rd quarter worth approximately $29,425,000. Finally, New York State Common Retirement Fund grew its stake in shares of BioNTech by 457.9% in the 3rd quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after purchasing an additional 178,981 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.